MDT

95.67

+0.05%↑

VEEV

284.1

+0.39%↑

A

143.59

+1.19%↑

HQY

93.05

+2.04%↑

TLRY

1.59

+2.58%↑

MDT

95.67

+0.05%↑

VEEV

284.1

+0.39%↑

A

143.59

+1.19%↑

HQY

93.05

+2.04%↑

TLRY

1.59

+2.58%↑

MDT

95.67

+0.05%↑

VEEV

284.1

+0.39%↑

A

143.59

+1.19%↑

HQY

93.05

+2.04%↑

TLRY

1.59

+2.58%↑

MDT

95.67

+0.05%↑

VEEV

284.1

+0.39%↑

A

143.59

+1.19%↑

HQY

93.05

+2.04%↑

TLRY

1.59

+2.58%↑

MDT

95.67

+0.05%↑

VEEV

284.1

+0.39%↑

A

143.59

+1.19%↑

HQY

93.05

+2.04%↑

TLRY

1.59

+2.58%↑

Search

Incyte Corp

Открыт

СекторЗдравоохранение

87.06 -0.57

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

83.88

Макс.

87.56

Ключевые показатели

By Trading Economics

Доход

247M

405M

Продажи

163M

1.2B

P/E

Средняя по отрасли

20.031

36.442

Рентабельность продаж

33.319

Сотрудники

2,617

EBITDA

324M

582M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-0.51% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

28 окт. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

3B

17B

Предыдущая цена открытия

87.63

Предыдущая цена закрытия

87.06

Новостные настроения

By Acuity

23%

77%

42 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Incyte Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

19 окт. 2025 г., 20:00 UTC

Приобретения, слияния, поглощения

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 окт. 2025 г., 23:44 UTC

Обсуждения рынка

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 окт. 2025 г., 23:37 UTC

Обсуждения рынка

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 окт. 2025 г., 23:36 UTC

Обсуждения рынка

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 окт. 2025 г., 23:36 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

19 окт. 2025 г., 23:09 UTC

Обсуждения рынка

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 окт. 2025 г., 22:41 UTC

Приобретения, слияния, поглощения

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 окт. 2025 г., 22:30 UTC

Отчет

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 окт. 2025 г., 22:18 UTC

Обсуждения рынка

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 окт. 2025 г., 21:50 UTC

Обсуждения рынка

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 окт. 2025 г., 21:15 UTC

Обсуждения рынка

Investors Need to Change Narrative Toward Scales -- Market Talk

19 окт. 2025 г., 19:34 UTC

Приобретения, слияния, поглощения

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 окт. 2025 г., 19:34 UTC

Приобретения, слияния, поглощения

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 окт. 2025 г., 19:33 UTC

Приобретения, слияния, поглощения

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 окт. 2025 г., 19:32 UTC

Приобретения, слияния, поглощения

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 окт. 2025 г., 19:32 UTC

Приобретения, слияния, поглощения

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 окт. 2025 г., 19:31 UTC

Приобретения, слияния, поглощения

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 окт. 2025 г., 19:31 UTC

Приобретения, слияния, поглощения

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 окт. 2025 г., 16:29 UTC

Отчет

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 окт. 2025 г., 11:14 UTC

Отчет

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 окт. 2025 г., 11:14 UTC

Отчет

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 окт. 2025 г., 11:14 UTC

Отчет

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 окт. 2025 г., 13:30 UTC

Приобретения, слияния, поглощения

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 окт. 2025 г., 13:30 UTC

Приобретения, слияния, поглощения

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 окт. 2025 г., 13:30 UTC

Приобретения, слияния, поглощения

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 окт. 2025 г., 13:30 UTC

Приобретения, слияния, поглощения

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 окт. 2025 г., 08:20 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

17 окт. 2025 г., 23:25 UTC

Приобретения, слияния, поглощения

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 окт. 2025 г., 22:15 UTC

Обсуждения рынка

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 окт. 2025 г., 21:15 UTC

Обсуждения рынка

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Сравнение c конкурентами

Изменение цены

Incyte Corp Прогноз

Целевая цена

By TipRanks

-0.51% падение

Прогноз на 12 месяцев

Средняя 87.12 USD  -0.51%

Максимум 115 USD

Минимум 60 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Incyte Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

19 ratings

8

Покупка

10

Удержание

1

Продажа

Техническая оценка

By Trading Central

59.52 / 62.66Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

42 / 371Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat